Management of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation.

A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing.

X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider.

An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial.

X. Long Zheng, MD, PhD, explains when physicians should administer caplacizumab after suspecting a diagnosis of acquired TTP, and discusses the risk of relapse or refractory disease.

X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment.